NIIMBL

announced 8 new technology and workforce projects in May 2026, including an enhanced end-to-end manufacturing testbed for fast, flexible drug-substance manufacturing.

Country: United States

Coverage

	EU	US
automation-robotics	✓	✓

Regulatorsfdaema

Verifiable facts

Fact	Value	Source
Affiliation	Public-private partnership part of the Manufacturing USA network, sponsored by NIST in the U.S. Department of Commerce, and organized by the University of Delaware	cbe.udel.edu · niimbl.org · nist.gov
Research focus	Biopharmaceutical manufacturing innovation, including real-time process analytics, AI/ML-based process optimization, novel protein expression platforms, and workforce development	manufacturingusa.com · niimbl.org · nist.gov
Facility	End-to-End Manufacturing Testbed located at NIIMBL headquarters in Delaware	niimbl.org
Grant	Project Call 9.1 awarded $9.7 million in May 2026; NIIMBL-led team awarded $10.5 million Gates Grand Challenges grant in October 2025	cbe.udel.edu · niimbl.org · nist.gov
Publications	Cumulative portfolio of 230 technical and workforce development projects since 2017 medium confidence	niimbl.org · nist.gov
Principal staff	Kelvin Lee (Director), Christopher J. Roberts (Associate Institute Director), John Balchunas (Workforce Director), and other leadership and senior fellows including John Erickson, Barry Buckland, and James Saylor	cbe.udel.edu · datanyze.com · niimbl.org · nist.gov
Headcount	Approximately 62-63 employees as of May 2026 medium confidence	aeroleads.com · datanyze.com

Independent sources: aeroleads.com · cbe.udel.edu · datanyze.com · manufacturingusa.com · nist.gov

Technologies

Name	Cluster	Risk
Scale-up centers for innovative biologic small-batch production	automation-robotics	Low	→

Compiled by BIOECON from primary sources.

Compliance Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.